Corcept Therapeutics annual operating margin
2009
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Corcept Therapeutics Operating Margin Growth & History (CORT)
Corcept Therapeutics's operating margin was 5.88% for fiscal 2025.
View full Corcept Therapeutics company overviewCorcept Therapeutics annual operating margin history
| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 5.88% | −14.40 pp |
| 2024 | 2024-12-31 | 20.29% | −1.95 pp |
| 2023 | 2023-12-31 | 22.24% | −5.79 pp |
| 2022 | 2022-12-31 | 28.03% | −5.98 pp |
| 2021 | 2021-12-31 | 34.01% | −2.22 pp |
| 2020 | 2020-12-31 | 36.23% | −0.19 pp |
| 2019 | 2019-12-31 | 36.41% | +0.79 pp |
| 2018 | 2018-12-31 | 35.62% | +2.42 pp |
| 2017 | 2017-12-31 | 33.20% | +20.68 pp |
| 2016 | 2016-12-31 | 12.52% | +19.36 pp |
| 2015 | 2015-12-31 | −6.85% | +97.18 pp |
| 2014 | 2014-12-31 | −104.02% | +296.63 pp |
| 2013 | 2013-12-31 | −400.66% | +696.17 pp |
| 2012 | 2012-12-31 | −1,096.82% | — |
| 2009 | 2009-12-31 | −69,827.59% | — |
Corcept Therapeutics quarterly operating margin
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 16.12% | +2.40 pp |
| Q1 2026 | 2026-03-31 | −30.08% | −32.25 pp |
| Q4 2025 | 2025-12-31 | 2.22% | −11.67 pp |
| Q3 2025 | 2025-09-30 | 4.92% | −20.61 pp |
| Q2 2025 | 2025-06-30 | 13.72% | −8.01 pp |
| Q1 2025 | 2025-03-31 | 2.17% | −17.92 pp |
| Q4 2024 | 2024-12-31 | 13.89% | −9.50 pp |
| Q3 2024 | 2024-09-30 | 25.53% | +0.30 pp |
| Q2 2024 | 2024-06-30 | 21.73% | −3.40 pp |
| Q1 2024 | 2024-03-31 | 20.09% | +6.04 pp |
| Q4 2023 | 2023-12-31 | 23.39% | +1.56 pp |
| Q3 2023 | 2023-09-30 | 25.22% | −6.17 pp |
| Q2 2023 | 2023-06-30 | 25.13% | −5.27 pp |
| Q1 2023 | 2023-03-31 | 14.06% | −14.51 pp |
| Q4 2022 | 2022-12-31 | 21.83% | −15.27 pp |
| Q3 2022 | 2022-09-30 | 31.39% | −6.30 pp |
| Q2 2022 | 2022-06-30 | 30.40% | −4.47 pp |
| Q1 2022 | 2022-03-31 | 28.57% | +3.85 pp |
| Q4 2021 | 2021-12-31 | 37.10% | +1.51 pp |
| Q3 2021 | 2021-09-30 | 37.69% | +9.06 pp |
| Q2 2021 | 2021-06-30 | 34.88% | −4.94 pp |
| Q1 2021 | 2021-03-31 | 24.72% | −15.72 pp |
| Q4 2020 | 2020-12-31 | 35.59% | −4.25 pp |
| Q3 2020 | 2020-09-30 | 28.63% | −11.86 pp |
| Q2 2020 | 2020-06-30 | 39.81% | +5.72 pp |
| Q1 2020 | 2020-03-31 | 40.44% | +11.20 pp |
| Q4 2019 | 2019-12-31 | 39.84% | +2.58 pp |
| Q3 2019 | 2019-09-30 | 40.49% | +4.85 pp |
| Q2 2019 | 2019-06-30 | 34.09% | +0.98 pp |
| Q1 2019 | 2019-03-31 | 29.24% | −7.17 pp |
| Q4 2018 | 2018-12-31 | 37.26% | −3.47 pp |
| Q3 2018 | 2018-09-30 | 35.64% | +3.78 pp |
| Q2 2018 | 2018-06-30 | 33.11% | −2.87 pp |
| Q1 2018 | 2018-03-31 | 36.41% | +19.24 pp |
| Q4 2017 | 2017-12-31 | 40.72% | +19.69 pp |
| Q3 2017 | 2017-09-30 | 31.86% | +17.72 pp |
| Q2 2017 | 2017-06-30 | 35.98% | +28.34 pp |
| Q1 2017 | 2017-03-31 | 17.17% | +13.49 pp |
| Q4 2016 | 2016-12-31 | 21.03% | +10.00 pp |
| Q3 2016 | 2016-09-30 | 14.14% | +13.37 pp |
| Q2 2016 | 2016-06-30 | 7.65% | +17.40 pp |
| Q1 2016 | 2016-03-31 | 3.69% | +43.58 pp |
| Q4 2015 | 2015-12-31 | 11.03% | +45.16 pp |
| Q3 2015 | 2015-09-30 | 0.77% | +70.85 pp |
| Q2 2015 | 2015-06-30 | −9.75% | +102.72 pp |
| Q1 2015 | 2015-03-31 | −39.89% | +252.03 pp |
| Q4 2014 | 2014-12-31 | −34.13% | +209.61 pp |
| Q3 2014 | 2014-09-30 | −70.08% | +299.70 pp |
| Q2 2014 | 2014-06-30 | −112.48% | +457.75 pp |
| Q1 2014 | 2014-03-31 | −291.92% | +345.41 pp |
| Q4 2013 | 2013-12-31 | −243.74% | +481.02 pp |
| Q3 2013 | 2013-09-30 | −369.78% | +357.33 pp |
| Q2 2013 | 2013-06-30 | −570.23% | +297.43 pp |
| Q1 2013 | 2013-03-31 | −637.33% | — |
| Q4 2012 | 2012-12-31 | −724.76% | — |
| Q3 2012 | 2012-09-30 | −727.11% | — |
| Q2 2012 | 2012-06-30 | −867.66% | — |
Corcept Therapeutics operating margin trends
Over the last five fiscal years, Corcept Therapeutics's operating margin decreased from 36.23% to 5.88%, a change of −30.34 percentage points. The latest reported quarter, Q2 2026, shows 16.12%.
About the metric
What operating margin means
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
Calculation and source
How operating margin is calculated
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Corcept Therapeutics source filings ↗Community posts
Corcept receives positive European recommendation for ovarian-cancer therapy
European drug advisers recommended approval of Corcept’s ($CORT) relacorilant, to be marketed as Lifyorli, in combination with nab-paclitaxel for platinum-resistant ovarian cancer. The positive opinion from the Committee for Medicinal Produ ...
